Disclosed are methods and kits for eliminating cancer cells and treating cancers by targeting neo splice sites or cryptic exons of oncogenic gene fusions.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
Disclosed are antibacterial compositions containing an amine amphenicol prodrug such as f lorf enicol amine and methods of using such compositions either alone or in combination with other antibacterial agents in methods of treating a non- tuberculosis mycobacteria infection and improving the efficacy of an antibacterial agent.
The present invention provides, in certain aspects, a natural killer (NK) cell that expresses all or a functional portion of interleukin-15 (IL-15), and methods for producing such cells. The invention further provides methods of using a natural killer (NK) cell that expresses all or a functional portion of interleukin-15 (IL-15) to treat cancer in a subject or to enhance expansion and/or survival of NK cells.
C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
4.
DISRUPTION OF KDM4A IN T CELLS TO ENHANCE IMMUNOTHERAPY
The application provides modified immune effector cells wherein a Lysine Demethylase 4A (KDM4A) gene or gene product is modified in the cell so that the expression and/or function of KDM4A in the cell is reduced or eliminated. The application also provides related pharmaceutical compositions and the methods for generating such modified immune effector cells. The application further provides uses of such modified immune effector cells for treating diseases such as cancers, infectious diseases and autoimmune diseases.
A61K 40/30 - Immunothérapie cellulaire caractérisée par l’expression recombinante de molécules spécifiques dans les cellules du système immunitaire
A61K 40/11 - Lymphocytes T, p. ex. lymphocytes infiltrant les tumeurs [TIL] ou lymphocytes T régulateurs [Treg]Cellules tueuses activées par les lymphokines [LAK]
This invention provides a method for inhibiting the growth of a pathogenic mold by contacting the pathogenic mold with a synergistically effective amount of an NK1 antagonisfand an antifungal agent. This invention also provides a method for inhibiting the growth of a mammalian fungal pathogen by contacting the mammalian fungal pathogen with a synergistically effective amount of posaconazole and rolapitant. In some aspects, the mammalian fungal pathogen is a species of Candida (e.g., C. glabrata, C. auris, C. albicans, C. dubliniensis, or C. parapsilosis). Aspergillus, Cryptococcus, Mucor, orRhizopus. In addition, A surface disinfectant comprising a synergistic amount of an NK1 antagonist and an antifungal agent in admixture with a carrier or excipient.
A01N 43/90 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés hétérocycliques comportant plusieurs hétérocycles déterminants condensés entre eux ou avec un système carbocyclique commun
A61K 31/438 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle le cycle étant condensé en spiro avec des systèmes carbocycliques ou hétérocycliques
6.
SMALL MOLECULE CEREBLON BINDERS THAT INDUCE THE DEGRADATION OF PROTEINS (KDM4B, VCL) RELEVANT TO CANCER
The present disclosure relates to compounds and compositions, and methods of uing the compounds and compositions for inducing the degradation of proteins that are relevant to cancer such as. for example. KDM4B and VCL. Also described are methods of treating cancer (e.g, a sarcoma, a carcinoma, a hematological cancer, a solid tumor, breast cancer, cervical cancer, gastrointestinal cancer, colorectal cancer, brain cancer, skin cancer, prostate cancer, ovarian cancer, non-small cell lung carcinoma, thyroid cancer, testicular cancer, pancreatic cancer, liver cancer, endometrial cancer, melanoma, glioma, leukemia, lymphoma, chronic myeloproliferative disorder, myelodysplastic syndrome, myeloproliferative neoplasm, plasma cell neoplasm (myeloma)) using the disclosed compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.
Disclosed are methods for transducing cells, e.g., NK cells, comprising: contacting the cells with a transduction composition, e.g., a virus particle, and a TBK1/IKKε inhibitor, e.g., the TBK1/IKKε inhibitor can comprise a substituted N-(3-((2-((3-(aminomethyl)-phenyl)amino)-5-methylpyrimidin-4-yl)amino)propyl)acetamide analogue; thereby transducing the cells. The virus particle can comprises a lentiviral vector. The present disclosure also relates to kits comprising: a TBK1/IKKε inhibitor; and instructions for transducing NK cells; wherein the TBK1/IKKε inhibitor comprises a substituted N-(3-((2-((3-(aminomethyl)-phenyl)amino)-5-methylpyrimidin-4-yl)amino)propyl)acetamide analogue. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.
The present disclosure relates to a method of treating a patient (e.g., a human patient) who has low-grade glioma by administering (e.g., orally) mirdametinib, or a pharmaceutically acceptable salt thereof, to the patient.
A61K 31/166 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide ayant l'atome de carbone d'un groupe carboxamide lié directement au cycle aromatique, p. ex. procaïnamide, procarbazine, métoclopramide, labétalol
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
The present disclosure relates generally to methods for generating a pre-effector gene signature for determining the cytotoxic effector potential of a preparation of chimeric antigen receptor (CAR) T cells comprising measuring single-cell gene expression data and endogenous T cell receptor (TCR) sequencing data of the preparation of CAR T cells. The present invention relates also to methods for determining the cytotoxic effector potential of a preparation of CAR T cells or a subset of CAR T cells therefrom as well as methods for treating a cancer in a subject in need thereof by administering a preparation of CAR T cells determined to have a cytotoxic effector potential.
The bioactive compounds of Ganoderma lucidum extract (GLE) responsible for anticancer activity were elucidated using NMR, X-ray crystallography and analogue derivatization, as well as anti-cancer activity studies. Structures of the seven most abundant GLE compounds are disclosed. Their selective efficacy against triple negative (TNBC) and inflammatory breast cancers (IBC) and other human cancer cell types (solid and blood malignancies) was shown, confirming potential their as anticancer agents.
A61K 31/575 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne d'au moins trois atomes de carbone, p. ex. cholane, cholestane, ergostérol, sitostérol
A61K 47/20 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant du soufre, p. ex. sulfoxyde de diméthyle [DMSO], docusate, laurylsulfate de sodium ou acides aminosulfoniques
G01N 33/58 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des substances marquées
11.
SMALL-MOLECULE MODULATORS OF LYMPHOCYTE-SPECIFIC PROTEIN TYROSINE KINASE AND CASEIN KINASE 1A
The present disclosure, in one aspect, relates to small molecules useful as modulators of cereblon protein. In another aspect, the present disclosure relates to small molecules useful as modulators of lymphocyte-specific protein tyrosine kinase (LCK) and/or casein kinase 1a (CK1a), methods of making same, pharmaceutical compositions comprising same, and methods of treating various clinical conditions and disorders using same, e.g., a disorder of uncontrolled cellular proliferation, such as a cancer, which may be associated with a LCK and/or CK1a protein dysfunction.
A61K 31/395 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines
A61K 31/167 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide ayant l'atome d'azote d'un groupe carboxamide lié directement au cycle aromatique, p. ex. lidocaïne, paracétamol
Disclosed is a method for preparing T cells for adoptive T cell therapy by contacting a population of activated T cells with an AT-rich interaction domain 1A (Aridla) inhibitor. Also disclosed is a kit, a population of T cells or engineered T cells produced by the method and use of the same in adoptive T cell therapy and the treatment of cancer.
C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
A61K 40/11 - Lymphocytes T, p. ex. lymphocytes infiltrant les tumeurs [TIL] ou lymphocytes T régulateurs [Treg]Cellules tueuses activées par les lymphokines [LAK]
H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (USA)
Inventeur(s)
Qi, Jun
Liu, Qi
Sigua, Logan Hunter
Durbin, Adam
Shendy, Noha
Schonbrunn, Ernst
Bikowitz, Melissa
Abrégé
The present disclosure relates to compounds, compositions, and methods for treating cancers mediated by aberrant Histone Acetyltransferase p300 (EP300) and/or CREB-Binding Protein (CBP) activity.
C07D 413/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
14.
BISPECIFIC CHIMERIC ANTIGEN RECEPTORS TARGETING GRP78 AND CD123 OR GRP78 AND B7H3
The application provides bispecific chimeric antigen receptors (CARs) targeting glucose-regulated-protein 78 (GRP78) and Cluster of Differentiation 123 (CD123) or GRP78 and B7-homolog 3 (B7H3). The application further provides polynucleotides and recombinant vectors encoding the CARs, as well isolated host cells and methods for preparing isolated host cells that express the CARs. The application further provides pharmaceutical compositions comprising the CAR modified cells and methods for treating a tumor using the CAR modified cells.
A61K 40/11 - Lymphocytes T, p. ex. lymphocytes infiltrant les tumeurs [TIL] ou lymphocytes T régulateurs [Treg]Cellules tueuses activées par les lymphokines [LAK]
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C07K 16/40 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre des enzymes
15.
KMT2A::AFF1 NEOANTIGEN AND USE THEREOF IN ADOPTIVE IMMUNOTHERAPY
KMT2A: :AFF1KMT2A: :AFF1 fusion neoantigen presented by HLA- DPAl*02 : 01 DPBl*01 : 01, polynucleotides encoding the recombinant T cell receptor, and an expression vector and recombinant host cell comprising such polynucleotides. A method of using the recombinant T cell receptor in adoptive immunotherapy for treating leukemia is also provided.
A61K 40/11 - Lymphocytes T, p. ex. lymphocytes infiltrant les tumeurs [TIL] ou lymphocytes T régulateurs [Treg]Cellules tueuses activées par les lymphokines [LAK]
16.
METHOD FOR IMPROVING AUDITORY PERCEPTION USING A VIPR1 INHIBITOR
Methods for increasing auditory cortex interneuron excitability and improving auditory perception, in particular pitch-discrimination acuity, are provided, which include the use of a Vasoactive Intestinal Peptide Receptor 1 (VIPR1) inhibitor.
The application provides modified immune effector cells with enhanced immune cell functions (e.g., enhanced anti-tumor effects), as well as related pharmaceutical compositions. The application further provides methods for generating the modified immune effector cells and methods for using the modified immune effector cells for treatment of diseases (e.g., adoptive cell therapy).
C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
A61K 40/11 - Lymphocytes T, p. ex. lymphocytes infiltrant les tumeurs [TIL] ou lymphocytes T régulateurs [Treg]Cellules tueuses activées par les lymphokines [LAK]
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
The application provides chimeric antigen receptors (CARs) that target leucine rich repeat containing 15 (LRRC15), and their uses in tumor immunotherapy. The application also provides polynucleotides and vectors that encode the CARs, as well as host cells comprising the CARs. The application also provides methods for preparing host cells comprising the CARs and methods for treating patients using the modified host cells.
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
19.
SUBSTITUTED N-((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-4-YL)METHYL)BENZAMIDE ANALOGS AS MODULATORS OF CEREBLON PROTEIN
In one aspect, the disclosure relates to substituted N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)methyl)benzamide analogs that useful as modulators of cereblon (CRBN) activity, methods of making same, pharmaceutical compositions comprising same, and methods of treating various clinical conditions and disorders using same, e.g., a disorder of uncontrolled cellular proliferation, such as a cancer, which may be associated with cereblon protein dysfunction. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.
C07D 401/04 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
A61K 31/454 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. pimozide, dompéridone
In one aspect, the disclosure relates to proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of LCK tyrosine kinase, i.e., the disclosed substituted N-(2-chloro-6-methylphenyl)-2-((6-(6-membered heterocycloalkyl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide analogues. The disclosed compounds are useful for modulating LCK tyrosine kinase activity through targeted degradation. In further aspects, the present disclosure relates to methods of making the disclosed compounds, pharmaceutical compositions comprising the disclosed compounds, and methods of treating various clinical conditions and disorders using same, e.g., a disorder of uncontrolled cellular proliferation, such as a cancer, which may be associated with a LCK tyrosine kinase dysfunction. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.
C07D 417/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
A61K 31/506 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime non condensées et contenant d'autres hétérocycles
A61K 31/55 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
Disclosed are methods for identifying or determining whether a subject exhibits a CD4+ memory T cell response to SARS-CoV-2 infection or vaccination, assessing the efficacy of a SARS-CoV-2 vaccine, and developing personalized SARS-CoV-2 treatment plans by detecting the presence and/or quantity of a particular T cell receptor a chain that recognizes a specific Spike protein epitope.
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
22.
REVERSE GENETICS VECTOR AND ASSOCIATED METHOD OF USE
A modified pHW2000 vector comprising an inactive T7 promoter is provided, as is a method for preparing an influenza virus vaccine using the modified vector.
Disclosed are methods for treating, preventing, reducing, or eliminating a manifestation or complication associated with sickle cell disease in a subject and improving the preparation of hematopoietic stem cells from a subject using senolytic agents such as Bcl inhibitors.
The present disclosure relates to methods of treating a coenzyme A reduction, elevation, sequestration, toxicity, or redistribution (CASTOR) disease such as, for example, defects in fatty acid oxidation enzymes, methylmalonic acidemia, glutaric acidemia, propionic academia, and HMG-CoA lyase, via small molecule modulators of CoA levels. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
A61K 31/501 - PyridazinesPyridazines hydrogénées non condensées et contenant d'autres hétérocycles
A61K 31/197 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino les groupes amino et carboxyle étant liés à la même chaîne carbone acyclique, p. ex. acide gamma-aminobutyrique [GABA], bêta-alanine, acide epsilon-aminocaproïque ou acide pantothénique
A61K 31/205 - Sels d'addition d'acides organiques avec des aminesSels d'ammonium quaternaire internes, p. ex. bétaïne, carnitine
A61P 3/00 - Médicaments pour le traitement des troubles du métabolisme
25.
Kit and Method for Analyzing T Cell Receptors from Single T Cells
A kit and method for analyzing nucleic acid molecules encoding T cell receptor (TCR) chains from individual T cells are disclosed. In particular, a method for analyzing individual T cells using high-throughput multiplex amplification and deep sequencing of nucleic acids encoding TCRs is provided.
The present application provides chimeric antigen receptors (CARs) comprising an anchoring domain, such as a PDZ binding motif, which binds to a cell polarity protein. Also provided are poly nucleotides encoding the CARs, vectors, and cell compositions comprising the same. Pharmaceutical compositions comprising the polypeptides, polynucleotides, vectors, or cells of the present disclosure, and their uses in treating a disease in a subject are also provided.
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
27.
SUBSTITUTED 2-(2-(2,6-DIOXOPIPERIDIN-3-YL)-1- OXOISOINDOLIN-5-YL) ACETAMIDE ANALOGS AS MODULATORS OF GSPT1 AND/OR IKZF1 PROTEIN
In one aspect, the disclosure relates to substituted 2-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)acetamide analogs that useful as modulators of GSPT1 and/or IKZF1 activity, methods of making same, pharmaceutical compositions comprising same, and methods of treating various clinical conditions and disorders using same, e.g., a disorder of uncontrolled cellular proliferation, such as a cancer, which may be associated with GSPT1 and/or IKZF1 protein dysfunction. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.
C07D 401/04 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
A61K 31/454 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. pimozide, dompéridone
A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol
An exemplary embodiment of the present disclosure provides systems and methods for mapping a location of cell types within a tissue sample. The system may include one or more processors, a non-transient memory in communication with the one or more processors storing instructions that when executed by the one or more processors are configured to perform method steps. The method may include receiving a tissue sample, capturing image data of the tissue sample, extracting a plurality of nucleic molecules from the tissue sample, and generating spatially resolved transcriptomic data from the extracted plurality of cellular analytes. The method may include determining cell-type reference data and generating a feature map of the tissue sample that includes a final inferred cell type compositional map for each tissue region of the tissue sample based on the spatially resolved transcriptomics data, the cell-type reference data, and the mapping estimate of cell types.
A 139-gene epigenetic signature for use in. methods for assessing the age and longevity of a T cell, selecting a T cell for a T cell therapy, and/or determining a T-cell acute lymphoblastic leukemia subtype is provided.
C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
C12Q 1/6806 - Préparation d’acides nucléiques pour analyse, p. ex. pour test de réaction en chaîne par polymérase [PCR]
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
30.
A SEQUENCE SELECTIVE DNA BINDING MOLECULE (SYNGRADER)
The present disclosure relates to chemical compounds that enable targeted degradation or non-proteolytic inactivation of DNDA binding proteins and confer selectivity of action on proteins that are bound to the genome, pharmaceutical compositions containing such compounds, and their use in treatment. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
C07D 403/14 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
A61K 31/395 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines
The application provides modified immune effector cells wherein the DNA (cytosine-5)-methyltransferase 3A (DNMT3A)-mediated de novo DNA methylation of the cell genome is inhibited, and IL10 signaling pathway is enhanced. The application also provides related pharmaceutical compositions and the methods for generating such modified immune effector cells. The application further provides uses of such modified immune effector cells for treating diseases such as cancers, infectious diseases and autoimmune diseases.
A recombinant AAV vector including an AAV2 P5 homologue or modified REP nicking site is described, wherein the recombinant AAV vector provides for a reduction in DNA contamination upstream of the PS promoter and improved purity.
Systems, methods, and compositions for the introduction of mutations to the proximal promoter region of the HBG1 and HBG2 genes are provided. Also included are cells and compositions of cells bearing one or more synthetic alleles formed by the disclosed systems, methods, and compositions. This disclosure also provides a method of treating a subject by introducing the disclosed synthetic allele(s) into a cell of a subject.
The application relates to chimeric receptors, particularly chimeric receptors comprising homodimeric polypeptides. Also disclosed are the uses of these receptors in tumor immunotherapy adoptive cell therapy). The application further relates to methods of genetically modifying therapeutic immune cells resulting in an enhanced immune response against a target antigen. Them application further relates to therapeutic cells that express the chimeric receptors and methods for treating patients using the modified therapeutic cells.
C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
35.
PHARMACOGENOMICS SCORE TO MAKE DECISIONS ON THERAPY AUGMENTATION IN AML
University of Florida Research Foundation, Incorporated (USA)
St. Jude Children's Research Hospital, Inc. (USA)
University of Tennessee Research Foundation (USA)
Inventeur(s)
Lamba, Jatinder Kaur
Elsayed, Abdelrahman H.
Cao, Xueyuan
Pounds, Stanley
Abrégé
The disclosure relates to methods for characterizing and/or treating a subject having cancer, said methods comprising performing an assay to identify the nucleotides present at each of a set of single-nucleotide polymorphism (SNP) locations within the cytarabine (ara-C) pathway, assigning a genotype score for the identified nucleotides of each SNP, and characterizing the subject having cancer based on the summation of the assigned genotype scores. In some embodiments, treatment is administered based upon the characterization of the subject, according to the methods described herein.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
C12Q 1/6874 - Méthodes de séquençage faisant intervenir des réseaux d’acides nucléiques, p. ex. séquençage par hybridation [SBH]
36.
USE OF PRIME EDITING FOR TREATING SICKLE CELL DISEASE
The present disclosure provides methods for treating sickle cell disease using prime editing. The present disclosure also provides epegRNAs targeting the β-globin (HBB) gene, which may be useful for treating sickle cell disease. Also provided herein are prime editor complexes, polynucleotides, vectors, pharmaceutical compositions, kits, and cells useful for performing the methods described herein.
The present disclosure relates to chemical compounds that modulate pantothenate kinase (PanK) activity for the treatment of metabolic disorders (such as diabetes mellitus type II), neurologic disorders (such as pantothenate kinase-associated neurodegeneration), pharmaceutical compositions containing such compounds, and their use in treatment. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
C07D 403/04 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
A61K 31/197 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino les groupes amino et carboxyle étant liés à la même chaîne carbone acyclique, p. ex. acide gamma-aminobutyrique [GABA], bêta-alanine, acide epsilon-aminocaproïque ou acide pantothénique
38.
INTERFERONS AND NUCLEAR EXPORT INHIBITORS FOR USE IN METHODS OF TREATING CANCER
Methods for inducing inflammatory cell death and treating cancer are provided, which include the targeting of a component of the ZBP1-ADAR1 PANoptosis pathway and the use of a combination of one or more interferons or one or more agents that upregulate interferon production and one or more nuclear export inhibitors.
The present invention is directed to methods for treating cancer by targeting glutamine levels in tumors and/or glutamine-dependent signaling in dendritic cells, including the modulation of glutamine levels as means to enhance the efficacy of cancer immunotherapies.
A61K 31/198 - Alpha-amino-acides, p. ex. alanine ou acide édétique [EDTA]
A61K 35/15 - Cellules de la lignée des myéloïdes, p. ex. granulocytes, basophiles, éosinophiles, neutrophiles, leucocytes, monocytes, macrophages ou mastocytesCellules précurseurs myéloïdesCellules présentatrices d’antigène, p. ex. cellules dendritiques
A61P 35/04 - Agents anticancéreux spécifiques pour le traitement des métastases
Testis-restricted melanoma antigen (MAGE) proteins are frequently hijacked in cancer and play a critical role in tumorigenesis. These proteins assemble with E3 ubiquitin ligases and function as substrate adaptors that direct the ubiquitination of novel targets, including key tumor suppressors. However, the development of MAGE-directed therapeutics heretofore has been extremely limited. In one aspect, the disclosure relates to compounds and peptides useful as inhibitors of MAGE-All: substrate interaction, methods of making same, pharmaceutical compositions comprising same, and methods of treating a disorder associated with a MAGE-All dysfunction. e.g., a cancer, using same. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.
C07D 405/12 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
A61K 31/4706 - 4-Aminoquinoléines8-Aminoquinoléines, p. ex. chloroquine, primaquine
A61K 31/4709 - Quinoléines non condensées contenant d'autres hétérocycles
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
C07D 215/46 - Atomes d'azote liés en position 4 avec des radicaux hydrocarbonés, substitués par des atomes d'azote, liés auxdits atomes d'azote
C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
41.
CHIMERIC ANTIGEN RECEPTORS TARGETING SPLICE VARIANTS OF THE EXTRACELLULAR MATRIX PROTEINS TENASCIN C (TNC) AND PROCOLLAGEN 11A1 (COL11A1)
The application provides chimeric antigen receptors (CARs) that target splice variants of the extracellular matrix proteins tenascin C (TNC) and procollagen 11A1 (Col11A1), and their uses in tumor immunotherapy. The application also provides polynucleotides and vectors that encode the chimeric antigen receptors, as well as host cells comprising the chimeric antigen receptors. The application also provides methods for preparing host cells comprising the chimeric antigen receptors and methods for treating patients using the modified host cells.
UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (USA)
Inventeur(s)
Winston, Stephen
Davidoff, Andrew
Wiggins, Kristin
Schultz-Cherry, Stacey
Ross, Ted M.
Abrégé
A self-adj uvating recombinant, non-replicating Adeno-Associated Virus (AAV) vector harboring nucleic acids encoding one or more immunogenic peptides or proteins, wherein said nucleic acids include a plurality of immunostimulatory CpG motifs is provided. Also disclosed are immunogenic compositions and methods of eliciting an immune response using the AAV vector.
The invention provides a chimeric receptor comprising NKG2D, DAP10 and CD3 zeta. Also disclosed is a composition comprising this chimeric receptor and methods for making and using it to enhance the cytotoxicity and antitumor capacity of NK cells. The invention also encompasses methods for use of NKG2D-DAP10-CD3 zeta polypeptides, vectors and cells in methods for treating cancer and other proliferative disorders, as well as infectious diseases.
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
St. Jude's Children's Research Hospital, Inc. (USA)
Inventeur(s)
Pardoll, Drew M.
Huang, Ching-Tai
Powell, Jonathan
Drake, Charles G.
Vignali, Dario A.
Workman, Creg J.
Abrégé
Regulatory T cells (Treg) limit autoimmunity but can also attenuate the magnitude of anti-pathogen and anti-tumor immunity. Understanding the mechanism of Treg function and therapeutic manipulation of Treg in vivo requires identification of Treg selective receptors. A comparative analysis of gene expression arrays from antigen specific CD4+ T cells differentiating to either an effector/memory or a regulatory phenotype revealed Treg selective expression of LAG-3 (CD223), a CD4-related molecule that binds MHC class II. LAG-3 expression on CD4+ T cells correlates with the cells' in vitro suppressor activity, and ectopic expression of LAG-3 on CD4 T cells confers suppressor activity on the T cells. Antibodies to LAG-3 inhibit suppression both in vitro and in vivo. LAG-3 marks regulatory T cell populations and contributes to their suppressor activity.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A01K 67/0271 - Vertébrés chimériques, p. ex. comprenant des cellules exogènes
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
C07K 16/42 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre des immunoglobulines (anticorps anti-idiotypiques)
C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
A61K 35/12 - Substances provenant de mammifèresCompositions comprenant des tissus ou des cellules non spécifiésCompositions comprenant des cellules souches non embryonnairesCellules génétiquement modifiées
45.
METHODS FOR IMPROVED RISK STRATIFICATION OF ADULT AND PEDIATRIC ACUTE MYELOID LEUKEMIA PATIENTS USING INFLAMMATION GENE SIGNATURES
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
Inventeur(s)
Aifantis, Iannis
Nadorp, Bettina
Sandler, Audrey, Lasry
Eisfeld, Ann-Kathrin
Gruber, Tanja
Pounds, Stanley
Abrégé
The disclosed technology relates to methods for improved risk stratification of Acute Myeloid Leukemia (AML.) patients, and more particularly, for improved risk stratification of adult and pediatric AML patients using inflammation gene signatures (iScore).
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
G16B 25/10 - Profilage de l’expression de gènes ou de protéinesEstimation ou normalisation de ratio d’expression
46.
NLRP12 AND NLRC5 MODULATORS AND METHODS FOR USING THE SAME TO MODULATE DISEASES
Disclosed are compositions and methods for using heme and at least one PAMP and/or DAMP molecule for activating NLRP12 and/or NLRC5 and inflammatory cell death. Also provided is a screening assay for identifying NLRP12 and/or NLRC5 inhibitors and use of such inhibitors in the treating or ameliorating of NLRP12-mediated or NLRC5-mediated inflammation associated with a hemolytic disease, infectious disease, cancer, or inflammatory syndrome.
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
A61K 31/555 - Composés hétérocycliques contenant des métaux lourds, p. ex. hémine, hématine, mélarsoprol
A61P 7/00 - Médicaments pour le traitement des troubles du sang ou du fluide extracellulaire
Methods and compositions using an inhibitor of EGFR signaling for prevention or an inhibitor of EGFR signaling and a nucleic acid molecule encoding an atonal-associated factor for treatment of hearing loss are described.
A61K 31/422 - Oxazoles non condensés et contenant d'autres hétérocycles
A61K 31/44 - Pyridines non condenséesLeurs dérivés hydrogénés
A61K 31/4706 - 4-Aminoquinoléines8-Aminoquinoléines, p. ex. chloroquine, primaquine
A61K 31/4709 - Quinoléines non condensées contenant d'autres hétérocycles
A61K 31/506 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime non condensées et contenant d'autres hétérocycles
A61K 31/517 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des systèmes carbocycliques, p. ex. quinazoline, périmidine
A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol
A61K 31/58 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes contenant des hétérocycles, p. ex. danazol, stanozolol, pancuronium ou digitogénine
A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
In one aspect, the disclosure relates to substituted N-(2-(2,6-dioxopiperidinyl-3-yl)-1,3-dioxoisoindolin-5-yl)arylsulfonamide analogs that useful as modulators of cereblon (CRBN) activity, methods of making same, pharmaceutical compositions comprising same, and methods of treating various clinical conditions and disorders using same, e.g., a disorder of uncontrolled cellular proliferation, such as a cancer, which may be associated with cereblon protein dysfunction and/or a GSPT1 dysfunction. In various further aspects, the disclosed compounds can selectively modulate the degradation of GSPT1 protein, i.e., the disclosed compounds can act as GSPT1 degraders. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.
C07D 401/04 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
A61K 31/45 - Pipéridines non condensées, p. ex. pipérocaïne ayant des groupes oxo liés directement à l'hétérocycle, p. ex. cycloheximide
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61P 35/02 - Agents anticancéreux spécifiques pour le traitement de la leucémie
C07D 405/14 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
C07D 409/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
C07D 413/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
49.
METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTOR
The present disclosure relates to methods of identifying subjects in need of treatment for, e.g., a coenzyme A reduction, elevation, sequestration, toxicity, or redistribution (CASTOR) disease such as, for example, defects in fatty acid oxidation enzymes, methylmalonic acidemia, glutaric acidemia, propionic academia, and HMG-CoA lyase, via small molecule modulators of CoA levels. The methods may comprise assessing levels of carnitines, CoA, and/or various metabolites and biomarkers and administration of therapeutics useful in the treatment of CASTOR disorders, metabolic diseases, and/or neurological diseases. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present inventions.
A61K 31/501 - PyridazinesPyridazines hydrogénées non condensées et contenant d'autres hétérocycles
A61P 3/00 - Médicaments pour le traitement des troubles du métabolisme
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
The present invention relates to a chimeric receptor capable of signaling both a primary and a co-stimulatory pathway, thus allowing activation of the co-stimulatory pathway without binding to the natural ligand. The cytoplasmic domain of the receptor contains a portion of the 4-1BB signaling domain. Embodiments of the invention relate to polynucleotides that encode the receptor, vectors and host cells encoding a chimeric receptor, particularly including T cells and natural killer (NK) cells and methods of use.
C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
51.
DISRUPTION OF ASXL1 IN T CELLS TO ENHANCE IMMUNOTHERAPY
The application relates to modified immune effector cells with enhanced immune cell function, as well as related pharmaceutical compositions. The application further relates to methods for generating the modified immune effector cell and methods for using the modified immune effector cell for treatment of diseases (e.g., adoptive cell therapy).
C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
Provided herein are compositions and methods for accurate and scalable Primary Template-Directed Amplification (PTA) nucleic acid amplification and sequencing methods, and their applications for research, diagnostics, and treatment.
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
53.
SUBSTITUTED 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE/2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE-1,3-DIONE ANALOGS AS MODULATORS OF CEREBLON PROTEIN
The present disclosure relates to substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione/2-(6-dioxopiperidin-3-yl) isoindoline-1,3-dione analogs that useful as modulators of cereblon (CRBN) activity, methods of making same, pharmaceutical compositions comprising same, and methods of treating various clinical conditions and disorders using same, e.g., a disorder of uncontrolled cellular proliferation, such as a cancer, which may be associated with cereblon protein dysfunction.
A61K 31/403 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil condensés avec des carbocycles, p. ex. carbazole
Methods for treating or mitigating COVID-19, sepsis or hemophagocytic lymphohistiocystosis or cytokine storm-associated syndromes; and treating or preventing inflammatory cell death associated with an inflammatory condition or infection such as SARS-CoV-2, or inducing inflammatory cell death in the context of cancer are provided, which includes the modulation of TNF and/or IFN-γ activity.
C07K 16/24 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons
A61P 37/06 - Immunosuppresseurs, p. ex. médicaments pour le traitement du rejet de greffe
Compositions for identifying a pathogenic bacterial infection include a mannitol compound with one or more substituents including radioisotopes. These radiopharmaceuticals, such as a positron- emitting mannitol analogue, [18F]fluoromannitol ([18A. baumanniiS. epidermisP.mirabilisS. entericaK. pneumonia,E. faecium E. cloacaeM. marinumM. marinum, but not non-active infection sites such as sterile inflammatory sites, cancer sites, etc. Administration of these radiopharmaceuticals to and subsequent imaging of patients, e.g., via positron emission tomography (PET), enables detection of deep-seated and difficult to manage bacterial infections, such as osteomyelitis and prosthetic joint infection, or in patients with sickle cell disease. [18F]FMtl injection detects and differentiates infection rapidly. The radiolabeled mannitol compounds can be produced via nucleophilic substitution reactions that are deployable on commercially available synthesizers, facilitating straightforward and wide accessibility, and counteracting unnecessary antibiotic use.
The application provides modified immune effector cells wherein a Lysine Demethylase 4A (KDM4A) gene or gene product is modified in the cell so that the expression and/or function of KDM4A in the cell is reduced or eliminated. The application also provides related pharmaceutical compositions and the methods for generating such modified immune effector cells. The application further provides uses of such modified immune effector cells for treating diseases such as cancers, infectious diseases and autoimmune diseases.
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
This invention provides a method for inhibiting the growth of a pathogenic mold by contacting the pathogenic mold with a synergistically effective amount of an NK1 antagonisfand an antifungal agent. This invention also provides a method for inhibiting the growth of a mammalian fungal pathogen by contacting the mammalian fungal pathogen with a synergistically effective amount of posaconazole and rolapitant. In some aspects, the mammalian fungal pathogen is a species of Candida (e.g., C. glabrata, C. auris, C. albicans, C. dubliniensis, or C. parapsilosis), Aspergillus, Cryptococcus, Mucor, or Rhizopus. In addition, A surface disinfectant comprising a synergistic amount of an NK1 antagonist and an antifungal agent in admixture with a carrier or excipient.
A61K 31/438 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle le cycle étant condensé en spiro avec des systèmes carbocycliques ou hétérocycliques
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
58.
METHODS FOR TREATING OR REDUCING THE SEVERITY OF A VIRAL INFECTION
Methods for treating or reducing the severity of a viral infection such as SARS-CoV-2 are provided, which include the administration of a cortisol antagonist preferably in combination with an IL-6 antagonist.
C07K 16/24 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
The present disclosure provides chimeric MyD88 receptors. Also provided are polynucleotides encoding the chimeric MyD88 receptors, vectors comprising the polynucleotides encoding the chimeric MyD88 receptors, and cell compositions comprising the chimeric MyD88 receptors, polynucleotides and/or vectors. Pharmaceutical compositions comprising the polypeptides, polynucleotides, vectors, or cells of the present disclosure, and their uses in treating a disease in a subject are also provided.
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
The present invention provides methods of genetically modifying an immune cell such that the immune cell expresses a transgene in an activation dependent manner. The application also provides genetically modified immune cells prepared using such methods, and the uses of the genetically modified immune cells in immunotherapy (e.g., adoptive cell therapy) for treatment of a disease such as cancer, autoimmune disease or infectious disease.
Disclosed are methods and kits for eliminating cancer cells and treating cancers by targeting neo splice sites or cryptic exons of oncogenic gene fusions.
Disclosed is a method for preparing T cells for adoptive T cell therapy by contacting a population of activated T cells with an Eukaryotic Initiation factor-4A (eIF4A) inhibitor. Also disclosed is a kit, a population of T cells or engineered T cells produced by the method and use of the same in adoptive T cell therapy and the treatment of cancer.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
64.
Use of Amylase or Maltose to Treat or Prevent Neurodegeneration
A method for preventing or treating a neurodegenerative disease or condition by administering to a subject in need thereof an effective amount of an amylase or maltose is provided, wherein the amylase or maltose reduces aggregation-associated or misfolded protein- associated proteotoxicity, induces transcription of chaperones and proteases, promotes degradation of proteasome substrates, or preserves protein quality under stress conditions in a subject.
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
65.
METHOD FOR PREPARING T CELLS FOR ADOPTIVE T CELL THERAPY
Disclosed is a method for preparing T cells for adoptive T cell therapy by contacting a population of activated T cells with an Eukaryotic initiation factor-4A (eIF4A) inhibitor. Also disclosed is a kit, a population of T cells or engineered T cells produced by the method and use of the same in adoptive T cell therapy and the treatment of cancer.
The present invention provides a chimeric antigen receptor (CAR) comprising an extracellular target-binding domain comprising at least one glucose-regulated-protein 78 (GRP78)-binding moiety. The present invention further provides polynucleotides and recombinant vectors encoding such CARs. The present invention further provides isolated host cells and methods for preparing isolated host cells expressing the CARs. The present invention further provides pharmaceutical compositions comprising the host cells and methods for treating a tumor using the pharmaceutical compositions.
Mutation of adenosine methylation sites in nucleic acids encoding influenza virus hemagglutinin are provided that result in increases in vRNA, mRNA, and protein expression over time and increases in infectious titers when produced in mammalian cells.
Methods and formulations are provided for treating spinobulbar muscular atrophy in a subject in need thereof. By administering a therapeutically effective amount of a selective androgen receptor modulator or a small molecule such as 1-[2-(4-methylphenoxy)ethyl]-2-[(2-phenoxyethyl)sulfanyl]-1H-benzimidazole or a derivative, prodrug, or pharmaceutically acceptable salt thereof, one or more symptoms of spinobulbar muscular atrophy can be ameliorated. The effective amount can be effective to prevent or delay loss of body weight, a loss of mobility, and/or a loss of physical strength in the subject; to prevent or delay neurogenic atrophy and/or to prevent a loss of spinal cord motor neurons in the subject; to restore the frequency of type I myofibers to normal levels for a healthy subject; and/or to reverse testicular atrophy in the subject.
The present disclosure relates to a method of treating a patient (e.g., a human patient) who has low-grade glioma by administering (e.g., orally) mirdametinib, or a pharmaceutically acceptable salt thereof, to the patient.
A61K 31/166 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide ayant l'atome de carbone d'un groupe carboxamide lié directement au cycle aromatique, p. ex. procaïnamide, procarbazine, métoclopramide, labétalol
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
Disclosed is a method for preparing T cells for adoptive T cell therapy by contacting a population of activated T cells with an AT-rich interaction domain 1A (Aridla ) inhibitor. Also disclosed is a kit, a population of T cells or engineered T cells produced by the method and use of the same in adoptive T cell therapy and the treatment of cancer.
A01N 63/00 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des micro-organismes, des virus, des champignons microscopiques, des animaux ou des substances produites par, ou obtenues à partir de micro-organismes, de virus, de champignons microscopiques ou d'animaux, p. ex. enzymes ou produits de fermentation
C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
C12N 15/00 - Techniques de mutation ou génie génétiqueADN ou ARN concernant le génie génétique, vecteurs, p. ex. plasmides, ou leur isolement, leur préparation ou leur purificationUtilisation d'hôtes pour ceux-ci
A61K 31/44 - Pyridines non condenséesLeurs dérivés hydrogénés
Methods for increasing auditory cortex interneuron excitability and improving auditory perception, in particular pitch-discrimination acuity, are provided, which include the use of a Vasoactive Intestinal Peptide Receptor 1 (VIPR1 ) inhibitor.
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
C07K 14/72 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des hormones
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
72.
OBESE FERRET MODEL AND METHODS OF ESTABLISHING AND USING THE SAME
A method for establishing an obese ferret model by feeding a ferret with a diet having at least 25% of carbohydrate content for a period of time to provide the obese ferret model is disclosed as is a method of using said model to screen a substance for treating a respiratory infection.
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
73.
BISPECIFIC CHIMERIC ANTIGEN RECEPTORS TARGETING GRP78 AND CD123 OR GRP78 AND B7H3
The application provides bispecific chimeric antigen receptors (CARs) targeting glucose-regulated-protein 78 (GRP78) and Cluster of Differentiation 123 (CD123) or GRP78 and B7-homolog 3 (B7H3). The application further provides polynucleotides and recombinant vectors encoding the CARs, as well isolated host cells and methods for preparing isolated host cells that express the CARs. The application further provides pharmaceutical compositions comprising the CAR modified cells and methods for treating a tumor using the CAR modified cells.
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
St. Jude Children's Research Hospital, Inc. (Tunisie)
Inventeur(s)
Campana, Dario
Shook, David
Imamura, Masaru
Abrégé
The present invention provides, in certain aspects, a natural killer (NK) cell that expresses all or a functional portion of interleukin-15 (IL-15), and methods for producing such cells. The invention further provides methods of using a natural killer (NK) cell that expresses all or a functional portion of interleukin-15 (IL-15) to treat cancer in a subject or to enhance expansion and/or survival of NK cells.
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
The present application provides chimeric antigen receptors (CARs) comprising an anchoring domain, such as a PDZ binding motif, which binds to a cell polarity protein. Also provided are polynucleotides encoding the CARs, vectors, and cell compositions comprising the same. Pharmaceutical compositions comprising the polypeptides, polynucleotides, vectors, or cells of the present disclosure, and their uses in treating a disease in a subject are also provided.
A recombinant P5 promoter having an insertion of an exogenous spacer between the REP binding site and a transcription start site-localized Ying-Yang 1 (YY1) binding site is described, wherein said recombinant P5 promoter provides for a reduction in DNA contamination upstream of the P5 promoter without a concomitant reduction in viral titer.
A kit and method for analyzing nucleic acid molecules encoding T cell receptor (TCR) chains from individual T cells are disclosed. In particular, a method for analyzing individual T cells using high-throughput multiplex amplification and deep sequencing of nucleic acids encoding TCRs is provided.
C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
78.
Use of FOXP3 Enhancers to Modulate Regulatory T Cells
Disclosed are methods for modifying regulatory T cell lineage stability or induction by simultaneously modulating the activity of Foxp3 enhancers, CNS0 and CNS2 or CNS0 and CNS3. Methods for treating cancer, an autoimmune disease or condition, or a regulatory T cell-related disease or condition are also provided.
Recombinant Fibrinogen C Domain Containing 1 (rFibcd1) proteins and methods for using the same in the treatment of muscle atrophy are provided as are vectors, host cells, pharmaceutical compositions and modified RNA molecules encoding the rFibcd1 proteins.
A construct including a genomic insulator element that exhibits strong enhancer blocking activities in T lymphocytes is provided as are host cells, pharmaceutical compositions and methods of using the construct in the treatment of disease, in particular a disease to be treated with a retroviral vector-modified T lymphocyte.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
The present invention provides a chimeric antigen receptor (CAR) comprising an extracellular target-binding domain comprising a B7-H3 binding moiety. The present invention further provides polynucleotides and recombinant vectors encoding such CARs. The present invention further provides isolated host cells and methods for preparing isolated host cells expressing the CARs. The present invention further provides pharmaceutical compositions comprising the isolated host cells and methods for treating a tumor using the pharmaceutical compositions.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
In one aspect, the disclosure relates to proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of LCK tyrosine kinase, i.e., the disclosed substituted N-(2-chloro-6-methylphenyl)-2-((6-(6-membered heterocycloalkyl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide analogues. The disclosed compounds are useful for modulating LCK tyrosine kinase activity through targeted degradation. In further aspects, the present disclosure relates to methods of making the disclosed compounds, pharmaceutical compositions comprising the disclosed compounds, and methods of treating various clinical conditions and disorders using same, e.g., a disorder of uncontrolled cellular proliferation, such as a cancer, which may be associated with a LCK tyrosine kinase dysfunction. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.
C07D 417/02 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles
A61K 31/427 - Thiazoles non condensés et contenant d'autres hétérocycles
In one aspect, the disclosure relates to substituted 2-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)acetamide analogs that useful as modulators of GSPT1 and/or IKZF1 activity, methods of making same, pharmaceutical compositions comprising same, and methods of treating various clinical conditions and disorders using same, e.g., a disorder of uncontrolled cellular proliferation, such as a cancer, which may be associated with GSPT1 and/or IKZF1 protein dysfunction. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.
A61K 31/395 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines
A61K 31/40 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil
84.
SUBSTITUTED N-((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-4- YL)METHYL)BENZAMIDE ANALOGS AS MODULATORS OF CEREBLON PROTEIN
In one aspect, the disclosure relates to substituted N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)methyl)benzamide analogs that useful as modulators of cereblon (CRBN) activity, methods of making same, pharmaceutical compositions comprising same, and methods of treating various clinical conditions and disorders using same, e.g., a disorder of uncontrolled cellular proliferation, such as a cancer, which may be associated with cereblon protein dysfunction. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.
A61K 31/454 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. pimozide, dompéridone
C07D 401/04 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
An exemplary embodiment of the present disclosure provides systems and methods for mapping a location of cell types within a tissue sample. The system may include one or more processors, a non-transient memory in communication with the one or more processors storing instructions that when executed by the one or more processors are configured to perform method steps. The method may include receiving a tissue sample, capturing image data of the tissue sample, extracting a plurality of nucleic molecules from the tissue sample, and generating spatially resolved transcriptomic data from the extracted plurality of cellular analytes. The method may include determining cell-type reference data and generating a feature map of the tissue sample that includes a final inferred cell type compositional map for each tissue region of the tissue sample based on the spatially resolved transcriptomics data, the cell-type reference data, and the mapping estimate of cell types.
C12Q 1/6881 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour le typage de tissu ou de cellule, p. ex. sondes d’antigène leucocytaire humain [HLA]
The application relates to chimeric cytokine receptors, particularly chimeric cytokine receptors comprising one or more leucine zipper motifs, and their uses in tumor immunotherapy (e.g., adoptive cell therapy). The application further relates to methods of genetically modifying therapeutic immune cells resulting in an enhanced immune response against a target antigen. The application further relates to therapeutic cells that express said chimeric cytokine receptors and methods for treating patients using the modified therapeutic cells.
C07K 14/715 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des cytokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des lymphokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des interférons
C12N 5/078 - Cellules du sang ou du système immunitaire
The present disclosure relates generally to methods for generating a pre-effector gene signature for determining the cytotoxic effector potential of a preparation of chimeric antigen receptor (CAR) T cells comprising measuring single-cell gene expression data and endogenous T cell receptor (TCR) sequencing data of the preparation of CAR T cells. The present invention relates also to methods for determining the cytotoxic effector potential of a preparation of CAR T cells or a subset of CAR T cells therefrom as well as methods for treating a cancer in a subject in need thereof by administering a preparation of CAR T cells determined to have a cytotoxic effector potential.
University of Florida Research Foundation, Incorporated (USA)
St. Jude Children's Research Hospital, Inc. (USA)
University of Tennessee Research Foundation (USA)
Inventeur(s)
Lamba, Jatinder Kaur
Pounds, Stanley
Elsayed, Abdelrahman H.
Cao, Xueyuan
Abrégé
Aspects of the disclosure relate to compositions and methods for predicting prognosis and classifying risk of subjects having certain cancers, for example acute myeloid leukemia (AML). In some embodiments, methods described by the disclosure comprise a step of assessing the mRNA expression of certain leukemic stem cell (LSC)-enriched genes in a subject to produce a predictive score for pediatric AML. In some embodiments, methods described by the disclosure comprise a step of assessing the mRNA expression of certain genes of pharmacological relevance for standard chemotherapy consisting of Cytarabine (also known as Ara-C), daunorubicin and etoposide in a subject to produce a predictive score for pediatric AML.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
G16B 25/10 - Profilage de l’expression de gènes ou de protéinesEstimation ou normalisation de ratio d’expression
A61P 35/02 - Agents anticancéreux spécifiques pour le traitement de la leucémie
89.
PHARMACOGENOMICS SCORE TO MAKE DECISIONS ON THERAPY AUGMENTATION IN AML
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. (USA)
UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (USA)
Inventeur(s)
Lamba, Jatinder, Kaur
Elsayed, Abdelrahman, H.
Cao, Xueyuan
Pounds, Stanley
Abrégé
The disclosure relates to methods for characterizing and/or treating a subject having cancer, said methods comprising performing an assay to identify the nucleotides present at each of a set of single-nucleotide polymorphism (SNP) locations within the cytarabine (ara-C) pathway, assigning a genotype score for the identified nucleotides of each SNP, and characterizing the subject having cancer based on the summation of the assigned genotype scores. In some embodiments, treatment is administered based upon the characterization of the subject, according to the methods described herein.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
A61P 35/02 - Agents anticancéreux spécifiques pour le traitement de la leucémie
90.
+ MEMORY T CELL RESPONSES TO SARS-COV-2 INFECTION OR VACCINATION
Disclosed are methods for identifying or determining whether a subject exhibits a CD4+ memory T cell response to SARS-CoV-2 infection or vaccination, assessing the efficacy of a SARS-CoV-2 vaccine, and developing personalized SARS-CoV-2 treatment plans by detecting the presence and/or quantity of a particular T cell receptor a chain that recognizes a specific Spike protein epitope.
The present invention provides chimeric cytokine receptors, particularly chimeric cytokine receptors that canbe activated in tumor microenvironment, and their uses in tumor immunotherapy (e.g., adoptive cell therapy). The present invention further provides methods of genetically modifying therapeutic cells resulting in an enhanced immune response against a target antigen. The application further provides therapeutic cells that express said chimeric cytokine receptors and methods for treating patients using the modified therapeutic cells.
C07K 14/715 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des cytokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des lymphokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des interférons
A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
Provided herein are compositions and methods for accurate and scalable Primary Template-Directed Amplification (PTA) nucleic acid amplification and sequencing methods, and their applications for research, diagnostics, and treatment.
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
93.
Method for Preparing CD7-Negative, CD3-Positive T Cells
Methods for preparing CD7-negative, CD3-positive T cells, which optionally express a chimeric antigen receptor, are provided as is a method of using such cells in a method for treating cancer, in particular a CD7+ cancer. In one aspect, the invention provides a method for preparing a population of CD7-negative, CD3-positive T cells by (a) performing a first selection by depleting, from a population of primary immune cells, cells that express CD7 thereby generating a population of CD7-negative cells; (b) performing a second selection by enriching, from the population of CD7-negative cells, T cells that express CD3 thereby generating a population of CD7-negative and CD3-positive T cells, and (c) incubating the population of CD7-negative and CD3-positive T cells in a culture vessel under stimulating conditions, thereby generating stimulated CD7-negative, CD3-positive T cells.
C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
B01D 15/38 - Adsorption sélective, p. ex. chromatographie caractérisée par le mécanisme de séparation impliquant une interaction spécifique non couverte par un ou plusieurs des groupes , p. ex. chromatographie d'affinité, chromatographie d'échange par ligand ou chromatographie chirale
94.
Methods and compositions for the prevention and treatment of hearing loss
In one aspect, pharmaceutical compositions comprising a CDK2 inhibitor and one or more of at least one agent known to treat a hearing impairment and at least one agent known to prevent a hearing impairment, and methods of treating and/or preventing hearing impairments or disorders using the compositions are disclosed. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
A61K 31/4015 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil ayant des groupes oxo liés directement à l'hétérocycle, p. ex. piracétam, éthosuximide
A61K 31/4155 - 1,2-Diazoles non condensés et contenant d'autres hétérocycles
A61K 31/454 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. pimozide, dompéridone
A61K 31/506 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime non condensées et contenant d'autres hétérocycles
A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61K 31/55 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole
The application provides modified immune effector cells wherein the DNA (cytosine-5)- methyltransferase 3A (DNMT3A)-mediated de novo DNA methylation of the cell genome is inhibited, and IL10 signaling pathway is enhanced. The application also provides related pharmaceutical compositions and the methods for generating such modified immune effector cells. The application further provides uses of such modified immune effector cells for treating diseases such as cancers, infectious diseases and autoimmune diseases.
Methods for inducing inflammatory cell death and treating cancer are provided, which include the targeting of a component of the ZBP1-ADAR1 PANoptosis pathway and the use of a combination of one or more interferons or one or more agents that upregulate interferon production and one or more nuclear export inhibitors.
Disclosed are methods for transducing cells, e.g., NK cells, comprising: contacting the cells with a transduction composition, e.g., a virus particle, and a TBK1/IKKε inhibitor, e.g., the TBK1/IKKε inhibitor can comprise a substituted N-(3-((2-((3-(aminomethyl)-phenyl)amino)-5-methylpyrimidin-4-yl)amino)propyl)acetamide analogue; thereby transducing the cells. The virus particle can comprises a lentiviral vector. The present disclosure also relates to kits comprising: a TBK1/IKKε inhibitor; and instructions for transducing NK cells; wherein the TBK1/IKKε inhibitor comprises a substituted N-(3-((2-((3-(aminomethyl)- phenyl)amino)-5-methylpyrimidin-4-yl)amino)propyl)acetamide analogue. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.
C12N 15/00 - Techniques de mutation ou génie génétiqueADN ou ARN concernant le génie génétique, vecteurs, p. ex. plasmides, ou leur isolement, leur préparation ou leur purificationUtilisation d'hôtes pour ceux-ci
C07D 413/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
98.
Methods and Kit for Analyzing Responsiveness of Patients to CD19 Immunotherapy
Kits and methods for determining resistance of a B-cell malignancy to blinatumomab immunotherapy and selecting a treatment for a subject with a B-cell malignancy based upon the expression level of an exon 2 intra-exonic splice variant of CD19 are provided.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61P 35/02 - Agents anticancéreux spécifiques pour le traitement de la leucémie
99.
T CELL GENE EXPRESSION ANALYSIS FOR USE IN T CELL THERAPIES
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
The invention is directed to methods and compositions for treating a disease associated with ventricular enlargement such as 22q11 deletion syndrome (22q11 DS) and schizophrenia (SCZ) by replenishment of decreased levels of miR-382-3p and/or miR-674-3p or inhibition of dopamine receptor Drd1 in ependymal cells.
